Archives of disease in childhoodJournal Article
15 Oct 2024
No abstract available
Competing interests: JEGC is a sub-investigator on the Merck Sharp & Dohme (MSD, a subsidiary of Merck) sponsored MK-1654-004 and MK-1654-007 studies of clesrovimab, an investigational extended half-life monoclonal antibody towards RSV fusion protein. He has not nor has ever been employed or funded by Merck.
Article info
Journal issue:
Doi:
10.1136/archdischild-2024-327741
Share: